BIOVICA

Q2 Interim report

Work with the FDA application progressing as planned

"The results from two additional studies with DiviTum® will be presented at San Antonio Breast Cancer Symposium, the world's largest scientific conference on breast cancer".

- Anders Rylander, CEO of Biovica

Period: May-October 2019/2020

SEK 000s	Q2 19/20	Q2 18/19	May-Oct 19/20	May-Oct 18/19	May-April 18/19
Net sales	1,249	68	1,616	981	3,005
Operating profit (loss)	-5,990	-5,609	-12,087	-9,566	-21,718
Profit (loss) for the period	-5,958	-5,563	-12,026	-9,592	-21,556
Earnings per share, before dilution	-0.25	-0.32	-0.51	-0.55	-1.23

Significant events during the second quarter

- Plan for clinical validation established following feedback from FDA
- Contract signed with leading US cancer group, SWOG, for analysis of major study where the results will be an important part of the FDA submission
- Timetable for 510(k) submission - now set for mid-2020

Significant events after the end of the period

- Otti Bengtsson Gref appointed as the new R&D Director, effective January 2020
- New results where DiviTum® has been validated as a dynamic biomarker for metastatic breast cancer in a collaborative study with Institut Curie in Paris accepted for presentation at the San Antonio Breast Cancer Symposium in December 2019
- DiviTum® – New clinical data that it is a strong prognostic marker in operable breast cancer. The results will be presented at the San Antonio Breast Cancer Symposium in December 2019

Audiocast	
When:	6 December 2019 at 10.00 CET
Where:	https://tv.streamfabriken.com/biovica-international-q2-2019 or SE: +46850558369 / DK: +4578150107 / UK: +443333009261 / US: +18335268384
Broadcast language:	in English

CEO's comments

Biovica is diligently working to launch DiviTum® in the US and European market for monitoring of early treatment effect of metastatic breast cancer. Events worth mentioning in Q2 include our meeting with the US Food and Drug Administration (FDA), progress with our clinical studies and more efforts with our commercial activities.

A market approval from the FDA is necessary in order to launch DiviTum® in USA as a tool for monitoring metastatic breast cancer. After having received written feedback from the FDA and meeting with them over the summer, we had a clear understanding of their requirements and are happy to report that the analytical validation is now progressing as planned and also showing good results. Furthermore, clinical validation is progressing as planned and the 1,500 samples to be analyzed have now been sent from USA. This comprehensive material that we received from the SWOG study (a study on metastatic breast cancer conducted by a US network of prominent oncologists) provides an excellent foundation that we will be able to reference in our FDA 510(k) submission. It also creates favorable conditions for clinical acceptance. Analytical and clinical validation are two important pieces of the puzzle for the submission and in summary, our work is progressing as planned for being able to submit the 510(k) towards the middle of next year.

As for our clinical studies, we obtained strong results subsequent to the end of the quarter in line with prior results, namely, that DiviTum® could be a valuable tool for ensuring that patients get the best possible results from their treatment. I would also like to highlight one of the studies that will be presented at the world's largest congress on breast cancer, SABCS, San Antonio Breast Cancer Symposium, during 10-14 December 2019. The study, which is based on more than 100 patients, was carried out in collaboration with the internationally renowned research center, Institut Curie. Results of the study show that DiviTum® can be used to monitor the treatment response of women with metastatic breast cancer. It supports the results from the TREnd study that was presented earlier in the year and it gives us much confidence in pursuing our plans for making DiviTum® a well-established biomarker for metastatic breast cancer.

Subsequent to the end of the quarter, we also announced clinical data demonstrating that DiviTum® is a strong prognostic marker in operable breast cancer. In particular, I would like to highlight a study that shows the prognostic effect of DiviTum®, making it possible to assess the risk of recurrence. That study will also be presented at SABCS in December. It was based on more than 600 patient samples. Adding that to the prior published study conducted in Israel in 2010, it means that we now have results from more than 800 patients. Our main focus area is still monitoring of metastatic breast cancer. However, these results help pave the way for expanding use of DiviTum® to other application areas, such as operable breast cancer, later on.

In total, we now have more than 10 studies encompassing more than 1,700 breast cancer patients. These studies create a unique value for DiviTum® and provide the foundation for commercialization of the product.

We appointed Otti Bengtsson Gref as our new R&D Director. She has leading expertise and extensive experience in developing diagnostic products that have obtained regulatory approval and successfully been launched on the market. She also has experience in production of this type of product, as well as an Executive MBA. We warmly welcome her to Biovica as a valuable addition to our team.

In summary, we are working diligently to achieve our goal of launching DiviTum® so that patients with metastatic breast cancer will receive the best possible treatment from day one. Our work with the FDA application is progressing as planned. We are reporting good results from studies and pursuing our commercialization plan. We have a unique product that meets an important need in a large, attractive market. The pieces are now in place for taking Biovica to the next level. I'm very much looking forward to the journey ahead with all of you.

Anders Rylander
CEO

Significant events during the period

Clinical validation plan set and timetable for FDA submission adjusted

We have signed an agreement with a leading US network for cancer research, SWOG, aimed at analyzing patient samples from a major study with DiviTum®. The results of the study will be an important component of our FDA submission. Based on feedback from the FDA, we've established the plan for our 510(k) submission in mid-2020.

Annual General Meeting (AGM)

The Annual General Meeting was held on 29 August 2019. The following individuals were re-elected to serve on the Board of Directors until the next AGM: Lars Holmqvist, Maria Holmlund, Ulf Jungnelius, Anders Rylander, Jesper Söderqvist. Henrik Osvald was newly elected to the Board of Directors. Lars Holmqvist was elected Chairman of the Board. Decisions were made on the following items:

- Guidelines for remuneration to senior executives.
- Process for appointing a nomination committee along with the work instructions that it should follow.
- Decision on granting the Board of Directors the authority to issue new shares for a maximum amount equal to 20 % of the current number of shares.
- A warrant scheme for staff of 270,000 warrants.

Significant events after the end of the period

New R&D Director appointed

Otti Bengtsson Gref has been appointed as Biovica's new R&D Director and she will also join the senior management team. Most recently, she worked as the R&D Director at Cavidi.

Otti Bengtsson Gref has extensive experience in leading positions in the area of R&D and in the commercial diagnostics industry. During the period 2010-2018, she had various managerial roles in R&D at IDD and Thermo Fisher Scientific. Prior to that, between 2003 and 2010, she worked as a specialist, product manager and was later was appointed Head of Product Management at Phadia. Bengtsson Gref has a Licentiate degree in Medicine, specialized in Immunology. She also has an Executive MBA degree. She will take over as R&D Director on 7 January 2020.

DiviTum® – Prognostic marker for treatment with CDK4/6 inhibitor

DiviTum® can be used as a dynamic, non-invasive biomarker for patients with metastatic breast cancer who are being treated with endocrine therapy and palbociclib. Data will be presented at the San Antonio Breast Cancer Symposium between 10-14 December 2019. It is the world's largest scientific conference with a focus on breast cancer.

The prognostic value of DiviTum® was evaluated in a prospective study of 103 patients with metastatic breast cancer who, between May 2016 and August 2018, received endocrine treatment and CDK 4/6 inhibitor palbociclib at Institut Curie in Paris. Plasma samples were collected prior to the start of treatment and again after four weeks of treatment. DiviTum® was used to measure thymidine kinase activity in the samples (pTKa).

Low DiviTum® values, compared to high values after four weeks of treatment, were associated with lower progression-free survival (10.4 versus 4.7 months) and total survival (not reached versus 20 months). Patients with a progression-free survival of less than 6 months had a significantly higher pTKa level after 4 weeks of treatment (median 256 Du/L versus 100 Du/L).

"We have shown the clinical validity of DiviTum in an adequately designed prospective trial of combined targeted and endocrine therapies. We are encouraged by these promising results showing the potential of DiviTum to become a clinically useful dynamic biomarker for monitoring efficacy of palbociclib and endocrine therapy in patients with metastatic breast cancer", said lead investigator Luc Cabel, MD, Institut Curie, Paris.

DiviTum® – Strong prognostic marker in operable breast cancer

DiviTum® is a strong prognostic marker in operable breast cancer. The results will be presented at the San Antonio Breast Cancer Symposium, SABCS, 10-14 December 2019.

The study is a retrospective analysis of serum samples from a random clinical study of 644 women with operable breast cancer (before menopause with HR+ breast cancer in stage II-IIIB). Serum samples were collected pre-operatively on the day of surgery. After five years, patients with

low pre-operative DiviTum values (the lowest quartile, <25 percent) showed a disease-free survival rate of 81 percent versus 58 percent in the group with the highest DiviTum values (>75 percent).

"We are thrilled to see these new, interesting results. It demonstrates that pre-operative DiviTum values measured in serum is a strong prognostic marker in operable breast cancer with a potential to identify patients with the most aggressive tumors in order to personalize their therapy," said lead investigator Dr. Luca Malorni, Prato Hospital, Italy.

Comments on the financial performance of the Group

Q2 - Sales and earnings

Net sales for the period amounted to SEK 1,249 (68) thousand. Sales during the period were to a customer in the research market that has been purchasing the kit for several years to conduct clinical studies.

Capitalized work performed by the company for its own use amounts to SEK 2,011 (1,655) thousand. The capitalized expenditure pertains to development efforts with DiviTum® for measuring thymidine kinase (TK).

Operating expenses amount to SEK -9,332 (-7,432) thousand. The higher level of expense compared to last year is attributable to having set up operations in USA. There was also a high level of activity in the DiviTum® project.

The operating loss for the period was SEK -5,990 (-5,609) thousand.

Net financial items amounted to SEK -36 (46) thousand. Loss after financial items was SEK -6,026 (-5,563) thousand. Loss for the period was SEK -5,958 (-5,563) thousand.

As of 31 October 2019, the company had 17 (17) employees, of which 8 (8) are women.

Q1 and Q2 - Combined sales and earnings

Net sales for the period amounted to SEK 1,616 (981) thousand. Sales during the period were to repeat customers in the research market who conduct clinical studies.

Capitalized work performed by the company for its own use amounts to SEK 3,369 (2,851) thousand. The capitalized expenditure pertains to development efforts with DiviTum® for measuring thymidine kinase (TK).

Operating expenses amount to SEK -17,442 (-13,671) thousand. The higher level of expense compared to last year is attributable to having set up operations in USA. There was also a high level of activity in the DiviTum® project.

The operating loss for the period was SEK -12,087 (-9,566) thousand.

Net financial items amounted to SEK -7 (-26) thousand. Loss after financial items was SEK -12,094 (-9,592) thousand. Loss for the period was SEK -12,026 (-9,592) thousand.

As of 31 October 2019, the company had 17 (17) employees, of which 8 (8) are women.

Financial position, cash flow and investments

The closing amount for cash & cash equivalents on 31 October 2019 was SEK 58,876 (31,268) thousand.

The year's capitalized expenditure for development work is SEK 3,369 (2,851) thousand.

Investments in property, plant and equipment in the form of equipment for the year is SEK 3,524 (0) thousand. All of the change is attributable to the implementation of IFRS 16 and lease agreements.

Related party transactions

During the year, the company, represented by parties related to the main owner and board member, Anders Rylander, leased office facilities to the Parent Company. The total fee for rent paid was SEK 99 thousand. Transactions were in accordance with market-based terms and conditions.

Policies for preparing the interim report

Accounting policies

This interim report was prepared in accordance with IAS 34, Interim Financial Reporting. The Group applies the Annual Accounts Act, International Financial Reporting Standards (IFRS) that have been adopted by the EU and RFR 1 Additional Accounting Regulations for Groups when preparing the financial statements. The Parent Company applies RFR 2 Accounting for Legal Entities when preparing the financial statements. The applied accounting policies otherwise correspond with those described in the Annual Report for 2018/2019.

Transition to IFRS 16 Leases

IFRS 16 has been implemented as of 1 May 2019. IFRS 16 replaces IAS 17 and the new standard involves new reporting requirements for the lessee. It requires a lessee to recognize assets and liabilities for all leases with a term of more than 12 months, unless the underlying asset is of low value. A lessee is required to recognize a right-of-use asset representing its right to use the underlying leased asset and a lease liability representing its obligation to make lease payments. With the new standard, leases that were reported as operating leases in the 2018/2019 financial year are, as of 1 May 2019, reported in accordance with IFRS 16. The cost of such leases is divided between interest expense and depreciation of the right-of-use asset. Biovica applies the simplified approach, which means that the comparative figures have not been restated. The company's lease portfolio consists of six agreements, which pertain to office space and vehicles. For one lease agreement on office equipment, the underlying assets were of lesser value and as such, recognition in accordance with IFRS 16 is not required.

During the period May-October 2019, the effect in the income statement amounts to SEK 69 thousand and in the balance sheet it is SEK 4,720 thousand, of which SEK 824 thousand is deferred tax that was not previously reported in the figures as of 1 May 2019.

SEK 000s	Reported balance sheet 2019-04-30	Adjustment to IFRS 16 2019-05-01	Adjusted balance sheet 2019-05-01
ASSETS			
Capitalized expenditure for R&D	31,560		31,560
Patents	6,347		6,347
Machinery, equipment, tools, fixtures and fittings	2,917	3,618	6,535
Total fixed assets	**40,825**	**3,618**	**44,443**
Inventories	446		446
Current receivables	2,758		2,758
Cash & cash equivalents including short-term investments	16,831		16,831
Total current assets	**20,035**	**0**	**20,035**
TOTAL ASSETS	**60,859**	**3,618**	**64,478**
EQUITY			
Total equity	52,098		52,098
Total non-current liabilities	940	2,543	3,483
Total current liabilities	7,822	1,075	8,897
TOTAL EQUITY AND LIABILITIES	**60,859**	**3,618**	**64,477**

Significant risks and uncertainties

There are several risks and uncertainties associated with the company's operations. For a more detailed description of the risks (in Swedish), please see the Annual Report for 2018/2019. The risks have not changed compared to what is described in the Annual Report.

Warrants

Program	To	Class B shares	Subscription price	Warrant price	Subscription period	Share capital increase	Number of class B shares
TO2	employees	200,000	25.00	0.54	29 March 2017 - 30 March 2020	13,333.33	200,000
TO3	employees	200,000	21.90	0.44	30 March 2020 - 25 August 2021	13,333.33	200,000
TO4	Board of Directors	175,000	19.50	0.94	25 March 2022 - 25 August 2023	11,666.67	175,000
TO5	employees	270,000	17.16	1.23	25 March 2021 - 25 August 2022	18,000.00	270,000
						56,333	**845,000**

Reclassification of shares

At the end of each quarter, class A shareholders are offered the opportunity of reclassifying their shares to B shares. A total of 42,488 shares were reclassified on 30 September 2019.

2019-09-30	Class A shares	Class B shares	Total
Before reclassification	7,293,688	16,279,684	23,573,372
Reclassification	-42,488	42,488	0
After reclassification	**7,251,200**	**16,322,172**	**23,573,372**

KPIs for the Group

SEK 000s	Q2 19/20	Q2 18/19	May-Oct 19/20	May-Oct 18/19	Full year 18/19
Net sales	1,249	68	1,616	981	3,005
Operating profit (loss)	-5,990	-5,609	-12,087	-9,566	-21,718
Profit (loss) for the period	-5,958	-5,563	-12,026	-9,592	-21,556
Capitalized R&D expenditure	2,011	1,655	3,369	2,851	6,464
Capitalized R&D exp., % of op. expenses	-22	-22	-19	-21	-22
Earnings per share, before dilution	-0.25	-0.32	-0.51	-0.55	-1.23
Earnings per share, after dilution	-0.24	-0.31	-0.49	-0.53	-1.18
Cash and cash equivalents at the end of the period	58,876	31,268	58,876	31,268	16,831
Cash flow from operating activities	-7,141	-4,763	-11,090	140	-17,967
Cash flow for the period	-9,338	-6,374	42,038	-10,859	-25,295
Equity	96,540	64,061	96,540	64,061	52,097
Equity per share	4.10	3.65	4.10	3.65	2.96
Equity ratio (%)	89	91	89	91	86
Average number of employees	17	17	17	17	16

Definitions are the same as those presented in the Annual Report for 2018/2019.

Consolidated income statement and summary statement of comprehensive income

SEK 000s	Q2 19/20	Q2 18/19	May-Oct 19/20	May-Oct 18/19	May-April 18/19
Net sales	1,249	68	1,616	981	3,005
Other income	166	107	371	346	932
Work performed by the company and capitalized	2,011	1,655	3,369	2,851	6,464
Change in WIP inventory	-83	-8	–	-73	43
	3,343	**1,823**	**5,355**	**4,105**	**10,444**
Materials cost	-26	-355	-306	-515	-875
Other external costs	-2,969	-2,130	-5,869	-4,237	-11,962
Employee benefit expenses	-5,049	-4,271	-9,199	-7,502	-16,245
Depreciation/amortization	-1,288	-675	-2,068	-1,414	-3,020
Other expenses	–	0	–	-2	-60
Operating profit (loss)	**-5,990**	**-5,609**	**-12,087**	**-9,566**	**-21,718**
Other interest income and similar profit or loss items	-58	-1	–	–	229
Interest expenses and similar items	22	47	-7	-26	-35
Profit (loss) before tax	**-6,026**	**-5,563**	**-12,094**	**-9,592**	**-21,524**
Tax expense	68	–	68	–	-32
Profit (loss) for the period	**-5,958**	**-5,563**	**-12,026**	**-9,592**	**-21,556**
Consolidated statement of comprehensive income					
Profit (loss) for the period	-5,958	-5,563	-12,026	-9,592	-21,556
Items that may be subsequently reclassified to profit and loss					
Exchange diff. foreign net invest.	–	–	–	–	–
Other comprehensive income for the period	–	–	–	–	–
Comprehensive income for the period	**-5,958**	**-5,563**	**-12,026**	**-9,592**	**-21,556**
Earnings per share					
Earnings per share, before dilution (SEK)	-0.25	-0.32	-0.51	-0.55	-1.23
Average number of shares, before dilution	23,573,372	17,573,372	23,573,372	17,573,372	17,573,372
Earnings per share, after dilution (SEK)	-0.24	-0.31	-0.49	-0.53	-1.18
Average number of shares, after dilution	24,418,372	17,968,332	24,418,372	17,968,332	18,343,372

Consolidated statement of financial position, in summary

SEK 000s	2019-10-31	2018-10-31	2019-04-30
ASSETS			
Intangible assets	40,138	35,432	37,907
Machinery, equipment, tools, fixtures and fittings	2,429	2,550	2,917
Right-of-use assets	3,083	–	–
Deferred tax asset	892	–	0
Total fixed assets	**46,541**	**37,982**	**40,825**
Inventories	272	330	446
Accounts receivable	1,504	4	1,732
Current receivables	1,044	706	1,026
Cash and cash equivalents	58,876	31,268	16,831
Total current assets	**61,696**	**32,308**	**20,035**
TOTAL ASSETS	**108,237**	**70,291**	**60,859**
EQUITY			
Share capital	1,572	1,172	1,172
Other contributed capital	176,868	133,776	133,776
Retained earnings (losses), including loss for the year	-81,900	-70,887	-82,850
Total equity	**96,540**	**64,061**	**52,097**
LIABILITIES			
Deferred tax liability	753	–	–
Lease liability	2,763	–	–
Other non-current liabilities	431	571	940
Total non-current liabilities	**3,947**	**571**	**940**
Current liabilities	8,181	5,658	7,822
TOTAL EQUITY AND LIABILITIES	**108,668**	**70,291**	**60,859**

Consolidated statement of changes in equity, in summary

SEK 000s	Share capital	Other contributed capital	Retained earnings	Profit (loss) for the year	Total equity
Opening balance, 1 May 2018	**1,172**	**133,776**	**-43,225**	**-18,010**	**73,713**
Appropriation in accordance AGM decision			-18,010	18,010	–
Adjustment			-59		-59
Translation difference					–
Profit (loss) for the period				-21,556	-21,556
Closing balance, 30 April 2019	**1,172**	**133,776**	**-61,294**	**-21,556**	**52,097**
Appropriation in accordance AGM decision			-21,556	21,556	–
Adjustment			-215		-215
New share issue	400	56,282			56,682
Translation difference		0			0
Profit (loss) for the period				-12,026	-12,026
Closing balance, 31 October 2019	**1,572**	**190,058**	**-83,065**	**-12,026**	**96,540**

Consolidated statement of cash flows, in summary

SEK 000s	Q2 19/20	Q2 18/19	May-Oct 19/20	May-Oct 18/19	May-April 18/19
Cash flow from operating activities before changes in working capital	-5,121	-4,901	-10,639	-7,937	-17,788
Changes in working capital	-2,020	138	-451	140	-179
Cash flow from operating activities	-7,141	-4,763	-11,090	-7,798	-17,967
Cash flow from investing activities	-1,540	-1,612	-2,897	-3,062	-7,329
Cash flow from financing activities	-657	–	56,025	–	–
Cash flow for the period	-9,338	-6,374	42,038	-10,859	-25,296
Cash and cash equivalents at the beginning of the period	68,207	37,642	16,831	42,127	42,127
Translation difference, cash and cash equivalents	7	–	7	–	–
Cash and cash equivalents at the end of the period	58,876	31,268	58,876	31,268	16,831

Parent Company income statement, in summary

SEK 000s	Q2 19/20	Q2 18/19	May-Oct 19/20	May-Oct 18/19	May-April 18/19
Net sales	1,249	68	1,616	981	3,005
Change in WIP inventory	-83	-8	–	-73	751
Work performed by the company and capitalized	2,011	1,655	3,369	2,851	6,464
Other operating income	131	107	336	346	43
Sales	*3,308*	*1,823*	*5,321*	*4,105*	*10,263*
Goods for resale	-26	-355	-306	-515	-875
Other external costs	-4,059	-2,080	-7,520	-4,237	-12,638
Employee benefit expenses	-4,388	-4,271	-8,121	-7,502	-15,736
Depreciation/amortization	-710	-707	-1,422	-1,414	-2,840
Other operating expenses	–	0	–	-2	-60
Operating expenses	*-9,184*	*-7,413*	*-17,369*	*-13,671*	*-32,149*
Operating profit (loss)	**-5,875**	**-5,591**	**-12,048**	**-9,566**	**-21,886**
Net financial income/expense	-192	45	-128	-26	280
Profit (loss) before tax	**-6,067**	**-5,546**	**-12,176**	**-9,592**	**-21,606**
Income tax	–	–	–	–	–
Profit (loss) for the period	**-6,067**	**-5,546**	**-12,176**	**-9,592**	**-21,606**
Earnings per share					
Earnings per share, before dilution (SEK)	-0.26	-0.32	-0.52	-0.55	-1.23
Average number of shares, before dilution	23,573,372	17,573,372	23,573,372	17,573,372	17,573,372
Earnings per share, after dilution (SEK)	-0.25	-0.31	-0.50	-0.53	-1.19
Average number of shares, after dilution	24,418,372	17,968,372	24,418,372	17,968,372	18,143,372

Comprehensive income (loss) equals the loss for the period.

Parent Company balance sheet, in summary

SEK 000s	2019-10-31	2018-10-31	2019-04-30
ASSETS			
Intangible assets	40,138	34,346	37,907
Machinery and equipment	1,516	2,053	1,801
Financial assets	1,237	173	300
TOTAL FIXED ASSETS	**42,891**	***36,571***	***40,008***
	–		
Inventories	272	338	446
Current receivables	2,584	1,574	3,738
Cash and cash equivalents	57,778	36,685	15,779
TOTAL CURRENT ASSETS	***60,634***	***38,597***	***19,963***
TOTAL ASSETS	**103,526**	**75,168**	**59,972**
EQUITY			
Total restricted equity	178,234	14,038	19,307
Total non-restricted equity	-81,722	55,527	32,699
TOTAL EQUITY	***96,512***	***69,565***	***52,005***
LIABILITIES			
Total non-current liabilities	–	100	–
Total current liabilities	7,014	5,503	7,966
TOTAL LIABILITIES	***7,014***	***5,603***	***7,966***
TOTAL EQUITY AND LIABILITIES	**103,526**	**75,168**	**59,972**

Board of Directors' assurance

The Board of Directors and CEO hereby certify that this interim report provides a true and fair summary of the Parent Company's and the Group's operations, earnings and financial position as well as describing any significant risks or uncertainties faced by the Parent Company or any of the companies belonging to the Group.

Uppsala 5 December 2019

Lars Holmqvist
Chairman of the Board

Jarl Ulf Jungnelius
Board Member

Maria Holmlund
Board Member

Jesper Söderqvist
Board Member

Henrik Osvald
Board member

Anders Rylander
Board member, CEO

This report has been reviewed by the company's auditor.

Calendar

Interim Report for Q3: November - January 2020	12 March 2020
Interim Report for Q4: February – April 2020	12 June 2020

For more information, please contact:

Anders Rylander, VD
Phone: +46 (0)18-44 44 835
Email: anders.rylander@biovica.com

Cecilia Driving, EVP CFO/HR/IR
Phone +46 (0)73 125 92 47
Email: cecilia.driving@biovica.com

Biovica International AB (publ), 556774-6150
Dag Hammarskjölds väg 54B
752 37 Uppsala
+46 (0)18-44 44 830

Biovica – Best possible treatment from day one

Biovica develops and commercializes blood-based biomarker assays for evaluating the effect of cancer treatments. Biovica's assay DiviTum® measures cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum® is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® has CE marking and it is registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se, +46 (0)8-528 00 399. For more information, please visit www.biovica.com.